Investment analysts at StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a report released on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
Shares of NASDAQ:GLMD opened at $0.31 on Thursday. Galmed Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $5.47. The business’s 50 day moving average is $0.37 and its 200-day moving average is $0.38. The firm has a market capitalization of $1.57 million, a PE ratio of -0.13 and a beta of 0.80.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last issued its earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
See Also
- Five stocks we like better than Galmed Pharmaceuticals
- Trading Stocks: RSI and Why it’s Useful
- Stock Impact: McDonald’s Price War with Starbucks, Wendy’s
- What Do S&P 500 Stocks Tell Investors About the Market?
- General Mills Q4 Sales Miss Expectations, Triggering Stock Drop
- What is Short Interest? How to Use It
- Enovix Stock Rises 35% in Short-Squeeze: This Rally Has Legs
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
